AR090455A1 - Metodos para preparar analogos de nucleotidos sustituidos - Google Patents

Metodos para preparar analogos de nucleotidos sustituidos

Info

Publication number
AR090455A1
AR090455A1 ARP130100924A ARP130100924A AR090455A1 AR 090455 A1 AR090455 A1 AR 090455A1 AR P130100924 A ARP130100924 A AR P130100924A AR P130100924 A ARP130100924 A AR P130100924A AR 090455 A1 AR090455 A1 AR 090455A1
Authority
AR
Argentina
Prior art keywords
methods
compound
formula
prepare analogs
replaced nucleotides
Prior art date
Application number
ARP130100924A
Other languages
English (en)
Inventor
Mkeon Bligh Cavan
Ibrahim Shereen
Anzalone Luigi
Liu Jyanwei
Serebryany Vladimir
Chun Jung Young
Jamison Rose Peter
Beigelman Leonid
Original Assignee
Alios Biopharma Inc
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc, Vertex Pharma filed Critical Alios Biopharma Inc
Publication of AR090455A1 publication Critical patent/AR090455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Se prepara un análogo de nucleótido de fosforotioato, que resultan de utilidad en el tratamiento de enfermedades y/o en afecciones tales como las infecciones virales. Reivindicación 1: Un método para preparar un compuesto de la fórmula (1) caracterizado porque el método comprende: acoplar un compuesto de la fórmula (A) y un compuesto de la fórmula (B), donde los grupos -OH y el grupo -NH del compuesto de la fórmula (A) están desprotegidos durante la reacción de acoplamiento.
ARP130100924A 2012-03-21 2013-03-21 Metodos para preparar analogos de nucleotidos sustituidos AR090455A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613758P 2012-03-21 2012-03-21
US201261734564P 2012-12-07 2012-12-07
US13/793,900 US8846896B2 (en) 2012-03-21 2013-03-11 Methods of preparing substituted nucleotide analogs

Publications (1)

Publication Number Publication Date
AR090455A1 true AR090455A1 (es) 2014-11-12

Family

ID=49212396

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100924A AR090455A1 (es) 2012-03-21 2013-03-21 Metodos para preparar analogos de nucleotidos sustituidos
ARP140100826A AR095217A1 (es) 2012-03-21 2014-03-11 Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140100826A AR095217A1 (es) 2012-03-21 2014-03-11 Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos

Country Status (9)

Country Link
US (2) US8846896B2 (es)
EP (1) EP2828278A4 (es)
CN (1) CN104334570B (es)
AR (2) AR090455A1 (es)
HK (1) HK1203513A1 (es)
NZ (1) NZ630800A (es)
TW (1) TWI617568B (es)
UY (1) UY34697A (es)
WO (1) WO2013142125A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012088155A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630800A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Methods of preparing substituted nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
EP2861611B1 (en) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Uracyl spirooxetane nucleosides
CA2894541A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014100505A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014164533A1 (en) * 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
ES2825035T3 (es) 2013-06-26 2021-05-14 Janssen Biopharma Inc Nucleósidos, nucleótidos y análogos de estos sustituidos con 4’-azidoalquilo
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201524990A (zh) * 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
JP6669675B2 (ja) 2014-06-24 2020-03-18 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
CA2952966A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3212657A4 (en) 2014-10-28 2018-04-11 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EP3265102A4 (en) 2015-03-06 2018-12-05 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
SG10202012214WA (en) 2017-02-01 2021-01-28 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN112630314B (zh) * 2020-11-06 2022-10-28 天地恒一制药股份有限公司 一种l-丙氨酸异丙酯盐酸盐与其对映异构体的分离方法
CN112645977A (zh) * 2020-12-23 2021-04-13 天津阿尔塔科技有限公司 一种脱异丙基巴胺磷的合成方法
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
CN1133642C (zh) * 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
KR101774429B1 (ko) * 2009-02-06 2017-09-04 코크리스탈 파마, 아이엔씨. 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭
EP2408306A4 (en) 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
EA025341B1 (ru) * 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012088155A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
NZ630800A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Methods of preparing substituted nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog

Also Published As

Publication number Publication date
NZ630800A (en) 2016-06-24
US8846896B2 (en) 2014-09-30
US8895723B2 (en) 2014-11-25
CN104334570B (zh) 2017-06-06
WO2013142125A1 (en) 2013-09-26
AR095217A1 (es) 2015-09-30
CN104334570A (zh) 2015-02-04
TW201343666A (zh) 2013-11-01
TWI617568B (zh) 2018-03-11
EP2828278A4 (en) 2015-12-09
HK1203513A1 (en) 2015-10-30
US20130253181A1 (en) 2013-09-26
EP2828278A1 (en) 2015-01-28
UY34697A (es) 2013-10-31
US20130281687A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AR090455A1 (es) Metodos para preparar analogos de nucleotidos sustituidos
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
MD20140112A2 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral
ECSP17072474A (es) Métodos para tratar infecciones por el virus filoviridae
ECSP15031144A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
NZ727392A (en) Methods of preparing substituted nucleotide analogs
CR20150370A (es) Compuestos antivirales
CA2807584C (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
BR112014005103A2 (pt) composições orgânicas para tratar doenças associadas com hsf1
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
UY33735A (es) Compuestos antivirales
UY33621A (es) Análogos de nucleótidos sustituidos
MX2016013151A (es) Nuevos derivados quinona de cannabidiol.
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
BR112013027098A2 (pt) produtos de vírus recombinante e métodos para inibição de expressão de miotilina
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure